 |
|
Protein may be strongest indicator of rare lung disease, study shows
June 04, 2009CINCINNATI-Researchers at the University of Cincinnati (UC) have discovered a protein in the lungs that can help in determining progression of the rare lung disease Idiopathic Pulmonary Fibrosis (IPF).
Researchers say the protein-Serum surfactant protein A-is superior to other IPF predictors and could lead to better decisions about treatment and timing of lung transplantation.
The study, led by Brent Kinder, MD, is published in the June 4 edition of the journal Chest.
Surfactant proteins are lipoproteins that allow the lungs to stretch and function. These have previously been investigated by UC pulmonary researchers Frank McCormack, MD, and Jeffrey Whitsett, MD.
Kinder and colleagues report that Serum surfactant protein A is the strongest predictor of a patient's survival in the first year after diagnosis with IPF.
"A simple blood test may give us the information we need to help determine the short term risk of death in a patient with IPF," says Kinder, an assistant professor of medicine at the UC College of Medicine and pulmonologist with UC Physicians. "This protein is a stronger predictor of the severity of illness than age, symptoms or prognostic data, like breathing tests."
IPF is scarring of the lung. As the disease progresses, air sacs in the lungs become replaced by fibrotic scar tissue. Lung tissue becomes thicker where the scarring forms, causing an irreversible loss of the tissue's ability to carry oxygen into the bloodstream.
IPF is one of about 200 disorders called interstitial lung diseases, which affect the thick tissue of the lung as opposed to more common lung ailments-such as asthma or emphysema-that affect the airways.
IPF is the most common form of interstitial lung diseases and affects about 128,000 people in the United States, with an estimated 48,000 new cases diagnosed each year. There currently are no proven therapies or cures for IPF.
Kinder, director of UC's Interstitial Lung Disease Center, says this new indicator will allow doctors to determine the severity of the disease in a fast, effective manner and will help them decide the best way to go about treating it.
"It will allow us to come to a decision about how or if to treat the IPF patient and get them enrolled in clinical trials immediately," he says. "In severe cases, it can help in scheduling a lung transplant at the most optimal time for the patient.
"Overall, this discovery could help us define the window of opportunity to appropriately try more aggressive therapies and could greatly help improve the lives of those living with IPF."
University of Cincinnati Academic Health Center
Surfactant proteins are lipoproteins that allow the lungs to stretch and function. These have previously been investigated by UC pulmonary researchers Frank McCormack, MD, and Jeffrey Whitsett, MD.
Kinder and colleagues report that Serum surfactant protein A is the strongest predictor of a patient's survival in the first year after diagnosis with IPF.
"A simple blood test may give us the information we need to help determine the short term risk of death in a patient with IPF," says Kinder, an assistant professor of medicine at the UC College of Medicine and pulmonologist with UC Physicians. "This protein is a stronger predictor of the severity of illness than age, symptoms or prognostic data, like breathing tests."
IPF is scarring of the lung. As the disease progresses, air sacs in the lungs become replaced by fibrotic scar tissue. Lung tissue becomes thicker where the scarring forms, causing an irreversible loss of the tissue's ability to carry oxygen into the bloodstream.
IPF is one of about 200 disorders called interstitial lung diseases, which affect the thick tissue of the lung as opposed to more common lung ailments-such as asthma or emphysema-that affect the airways.
IPF is the most common form of interstitial lung diseases and affects about 128,000 people in the United States, with an estimated 48,000 new cases diagnosed each year. There currently are no proven therapies or cures for IPF.
Kinder, director of UC's Interstitial Lung Disease Center, says this new indicator will allow doctors to determine the severity of the disease in a fast, effective manner and will help them decide the best way to go about treating it.
"It will allow us to come to a decision about how or if to treat the IPF patient and get them enrolled in clinical trials immediately," he says. "In severe cases, it can help in scheduling a lung transplant at the most optimal time for the patient.
"Overall, this discovery could help us define the window of opportunity to appropriately try more aggressive therapies and could greatly help improve the lives of those living with IPF."
University of Cincinnati Academic Health Center
Lung Disease Current Events and Lung Disease News RSSSurvey: Awareness of COPD is rising, but understanding is still low
Awareness of COPD-chronic obstructive pulmonary disease-continues to grow in the United States, according to national survey results released today by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health.
Multicenter study led by pitt finds early results of therapy for preemies not sustained
Inhaled nitric oxide (iNO), a therapy used in the treatment of premature newborns with respiratory failure that had shown promising results in short-term studies, does not significantly improve long-term outcomes, according to a national study led by critical care researchers at the University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh of UPMC.
Geneticists Hunt for Scleroderma Triggers
At its most benign, the autoimmune disease scleroderma can discolor parts of the skin of its sufferers. At its most pernicious, it can thicken and harden their skin, their blood vessels, and their internal organs before, in many cases, killing them.
Thyroid surgery safe for older patients, study finds
Thyroid surgery is safe for older patients, say physicians who found only slight differences in rates of complications and hospital readmissions in a multi-year study.
Drug could provide first treatment for scleroderma
Investigators have identified a drug that is currently approved to treat certain types of cancer, Gleevec, that could provide the first treatment for scleroderma, a chronic connective tissue disease for which a treatment has remained elusive.
People who work after retiring enjoy better health, according to national study
Retirees who transition from full-time work into a temporary or part-time job experience fewer major diseases and are able to function better day-to-day than people who stop working altogether, according to a national study.
UT scientists discover link between protein and lung disease
In a development that could lead to a novel approach to the treatment of a devastating lung disease, biochemists at The University of Texas Health Science Center at Houston report they are the first to link the osteopontin (OPN) protein to chronic obstructive pulmonary disease (COPD).
UAB Researchers Find TB-Prevention Therapy Is Cost-Effective Option
University of Alabama at Birmingham (UAB) researchers have found that the cost of preventive antibiotic tuberculosis (TB) therapy for patients infected by human immunodeficiency virus (HIV) is generally less expensive than the reported cost of treating newly confirmed TB cases.
New vaccine shows promise for COPD patients at risk for pneumonia
A new vaccine against pneumonia may offer better protection from chronic obstructive pulmonary disease (COPD) patients than the currently accepted vaccine, according to recent research that will be published in the September 15 issue of the American Journal of the Respiratory and Critical Care Journal, a publication of the American Thoracic Society.
New genes at work in patients with hereditary lung disease
University of Florida researchers have safely given new, functional genes to patients with a hereditary defect that can lead to fatal lung and liver diseases, according to clinical trial findings slated to appear this week in the online early edition of the Proceedings of the National Academy of Sciences.
More Lung Disease Current Events and Lung Disease News Articles
 |
Katzenstein and Askin's Surgical Pathology of Non-Neoplastic Lung Disease: Volume 13 in the Major Problems in Pathology Series by Anna-Luise A. Katzenstein MD (Editor) Here's a practical, concise manual for diagnosing biopsy specimens. It clarifies accepted diagnostic criteria for non-neoplastic lung diseases; establishes new criteria where needed; and emphasizes the important features in differential diagnosis. A generous bibliography is provided so that you can obtain more in-depth details if desired. The result is enough clearly presented information to enable you to diagnose the majority of non-neoplastic lung diseases without the need for an "expert" opinion. |
 |
Heart-lung Interactions in Health and Disease (Lung Biology in Health and Disease) by Scharf (Author) |
|
Sarcoidosis Vasculitis and Diffuse Lung Diseases by Mattioli 1885 Spa | |
 |
FlameEz-Lung, 60 Capsules/Bottle by FlameEz Chronic Obstructive Pulmonary Disease (COPD) is progressive inflammatory disease affecting the respiratory tract and the lungs. Inflammation causes destruction of airways and lung tissues. If inflammation persists, the damage to the airways and lungs may not be reversed. Recent studies also suggest that inflammation is a critical component in lung cancer development, progression and metastasis. Inflammation induces the release of a variety of inflammatory cytokines that cause oxidative damage, DNA mutation, and cell transformation. Inflammation also plays a key role in survival and expansion of tumor cells. Since tumor cells produce various substances that attract inflammatory cells, which are indispensable participants in tissue disruption and metastasis, inflammation has been described... |
 |
Understanding Lung Disease: Pulmonary Fibrosis Part of the award winning public television series Healthy Body/Healthy Mind. Pulmonary Fibrosis is a set of diseases that cause progressive scarring inside the lungs. Over time the lungs are slowly replaced with scar tissue, which causes airways to restrict airflow, making it difficult to breath and to get enough oxygen. Doctors, patients and researchers are hoping clinical trials will lead to a drug that prevents lung function from worsening ultimately allowing patients to live longer. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
 |
Understanding Lung Disease: Pulmonary Fibrosis Directed By: (c) Information Television Network |
 |
Early Differential Diagnosis and Treatment of Lung Disease (NCME Video 712) Also With: Network For Continuing Medical Education (Primary Contributor), Stephen I Rennard (Primary Contributor), Dennis E. Doherty (Primary Contributor), Nicholas Gross (Primary Contributor), Faroque A. Khan (Primary Contributor) In this program, a distinguished faculty uses a case-based format to probe challenges in the differential diagnosis and assessment of lung disease. The latest approaches to treatment are also reviewed. |
|
Happy Bunny ts Smoking Just Pay for the Lung Disease and Keep the Yellow Teeth as a Free Gift Adult Costume (XXlarge) by BJ Anti-Drug Campaign Basic t-shirt in black. Available in Medium, Large, XLarge and XXLarge | |
|
Lung Disease Awareness Ribbon Mouse Pad by MyHeritageWear.com The Lung Disease Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Lung Disease Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Lung Disease Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! | |
|
Happy Bunny ts Smoking Just Pay for the Lung Disease and Keep the Yellow Teeth as a Free Gift Adult Costume (Large) by BJ Anti-Drug Campaign Basic t-shirt in black. Available in Medium, Large, XLarge and XXLarge |
| © 2009 BrightSurf.com |